Direct evidence of nonadherence to antiepileptic medication in refractory focal epilepsy

Epilepsia

Volumn 54, Issue 1, 2013, Pages

  Carpentier, Nicolas ^a   Jonas, Jacques ^a,b   Frismand, Solène ^a   Vignal, Jean Pierre ^a,b   Rikir, Estelle ^a,c   Baumann, Cédric ^a   Lapicque, Françoise ^a,b   Saint Marcoux, Franck ^d   Vespignani, Hervé ^a,b   Maillard, Louis ^a,b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

Adherence; Antiepileptic drug; Drug resistant; Focal epilepsy; Overconsumption

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; TOPIRAMATE; VALPROIC ACID;

ADOLESCENT; ADULT; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG OVERDOSE; DRUG UNDERDOSE; FEMALE; FOCAL EPILEPSY; HOSPITALIZATION; HUMAN; MALE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFRACTORY FOCAL EPILEPSY; TREATMENT REFUSAL;

ADOLESCENT; ADULT; ANTICONVULSANTS; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84872088238     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2012.03695.x     Document Type: Article

References (12)

1. Bialer M, Midha KK,. (2010) Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability. Epilepsia 51: 941-950.
2. Gomes MM, Filho HS, Noé RA,. (1998) Anti-epileptic drug intake adherence. The value of the blood drug level measurement and the clinical approach. Arq Neuropsiquiatr 56: 708-713.
3. Helmstaedter C, Kurthen M, Lux S, Reuber M, Elger CE,. (2003) Chronic epilepsy and cognition: a longitudinal study in temporal lobe epilepsy. Ann Neurol 54: 425-432.
4. Kwan P, Brodie MJ,. (2001) Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet 357: 216-222.
5. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S, French J,. (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51: 1069-1077. Erratum in: (2010) Epilepsia 51:1922.
6. Luoni C, Bisulli F, Canevini MP, De Sarro G, Fattore C, Galimberti CA, Gatti G, La Neve A, Muscas G, Specchio LM, Striano S, Perucca E,. (2011) Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia 52: 2181-2191.
7. Paschal AM, Hawley SR, St Romain T, Ablah E,. (2008) Measures of adherence to epilepsy treatment: review of present practices and recommendations for future directions. Epilepsia 49: 1115-1122.
8. Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, Leppik IE, Tomson T, Perucca E,. (2008) Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 49: 1239-1276.
9. Perucca E,. (2002) Overtreatment in epilepsy: adverse consequences and mechanisms. Epilepsy Res 52: 25-33.
10. Sabaté E,. (2003) Adherence to long-term therapies: evidence for action. World Health Organization, Geneva.
11. Specht U, Elsner H, May TW, Schimichowski B, Thorbecke R,. (2003) Postictal serum levels of antiepileptic drugs for detection of noncompliance. Epilepsy Behav 4: 487-495.
12. Williams J, Bialer M, Johannessen SI, Krämer G, Levy R, Mattson RH, Perucca E, Patsalos PN, Wilson JF,. (2003) Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data. Epilepsia 44: 40-45.